RxDoctor Payments Data

Girish Murthy, MD

Infectious Disease · Ardmore, OKNPI 1013146398

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $10,200 of the $12,328 with a category attached, or 82.7%. AbbVie accounts for 97.2% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2019 at $4,206 and has fallen 98.4% since, to $68 in 2024. Among infectious disease clinicians in OK with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$12,328in general payments, 2019–2025

Across 49 payments — averaging $251.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$12K
  • Merck$155
  • Johnson & Johnson$56
  • Novartis$53
  • Inari Medical, Inc.$31
  • Penumbra, Inc.$25
  • plus $25 from 1 others

What the payments were for

  • Speaking & faculty fees$10,20083%
  • Travel & lodging$1,1159%
  • Food & beverage$1,0138%

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)36$11,983
Merck4$155
Johnson & Johnson2$56
Novartis3$53
Inari Medical, Inc.1$31
Penumbra, Inc.1$25
Pfizer2$25

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,328 in reported general payments places this provider in the 90th percentile of 51 infectious disease providers in Oklahoma.

See all infectious disease providers in Oklahoma

Medicare billing

Part B allowed, 2024
$149,572
Medicare patients
580
Services billed
1,809

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban38$22,576
Daptomycin14$6,955
Sucralfate27$2,807
Vancomycin Hcl37$2,522
Cefdinir103$1,212
Potassium Chloride109$842
Megestrol Acetate20$802
Midodrine Hcl20$672
Doxycycline Hyclate54$626
Torsemide52$481
Atorvastatin Calcium21$368
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav32$264
Dutasteride13$255
Bumetanide19$253
Pantoprazole Sodium30$232

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$25$22,57638 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 51 infectious disease providers in Oklahoma.

Other infectious disease in Ardmore

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →